Related Experiment Video
Updated: May 5, 2026
08:19
Author Spotlight: Unraveling the Mechanobiology of Tendon Impingement – A Multiaxial Murine Hind Limb Explant Model
Published on: December 8, 2023
921
Insertional Achilles Tendinopathy Treated With Botulinum Toxin: A Case Report.
Alexander Kim1, Alexander Knobloch1, Carlton Covey1
1Sports Medicine, David Grant Medical Center, Fairfield, USA.
Cureus
|September 11, 2024
Summary
This case study explores using Botulinum toxin A (BTX-A) injections for chronic insertional Achilles tendinopathy (IAT). Ultrasound-guided BTX-A may offer a new treatment option for recalcitrant heel pain.
Area of Science:
- Orthopedics
- Regenerative Medicine
- Musculoskeletal Disorders
Background:
- Chronic insertional Achilles tendinopathy (IAT) causes persistent heel pain and is often resistant to conservative treatments.
- Standard non-operative care includes eccentric exercises, with limited evidence for injection therapies like platelet-rich plasma (PRP).
- Surgical intervention is frequently considered for recalcitrant IAT cases.
Observation:
- Botulinum toxin A (BTX-A) is utilized for various musculoskeletal conditions, but its efficacy for Achilles tendinopathy remains unstudied.
- This report details a case of recalcitrant IAT managed with ultrasound-guided BTX-A injections.
Findings:
- The study presents a novel application of BTX-A for treating insertional Achilles tendinopathy.
- Ultrasound guidance was employed for precise delivery of BTX-A to the affected tendon insertion site.
Implications:
- BTX-A injections represent a potential new therapeutic avenue for managing chronic insertional Achilles tendinopathy.
- Further research is warranted to establish the efficacy and safety of BTX-A for this condition.
